Sinovac's CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Weidong Yin, Chairman, President & CEO, was presented with the Annual Innovation Award by China Central Television (CCTV).  As previously announced, Mr. Yin had been one of 18 nominees for the CCTV's China's 2009 Economic Man-of-the-Year.  Results were announced on December 23, 2009 at an award ceremony held in Beijing.
Mr. Weidong Yin was honored because of his contribution to the battle against the H1N1 influenza pandemic; Sinovac vaccines protect human life and strengthen the Chinese people's confidence.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "I am very pleased to have received CCTV's 2009 Annual Innovation Award.  As the first company worldwide to receive approval for the H1N1 vaccine, we have exemplified Sinovac's position as a true innovator in the global vaccine industry.  We are proud that our entire portfolio of innovative vaccines continues to make a significant contribution to the health and well-being of Chinese citizens."
Recipients of the Top Ten 2009 Economic Man-of-the-Year award were CEO and president of Sina Charles Chao, China Minsheng Banking Corporation Chairman Dong Wenbiao, Shenzhen Capital Group Chairman Jin Haitao, chairman of Geely Automobile Holding Li Shufu, Guangdong Galanz Enterprise Group CEO Liang
Chao-Hsien, chairman of Jiangsu Shagang Group Shen Wenrong, chairman and CEO at Neusoft Group Ltd Liu Jiren, Phoenix Publishing & Media Group chairman Tan Yue, Chongqing Changan Automobile Co., Ltd., chairman Xu Liuping, and chairman of New Oriental Education Group Yu Minhong.  In addition, Liu Haitao, head of Shanghai Institute of Microsystem and Information Technology under the Chinese Academy of Sciences, received the Annual Innovation Award.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccine.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any
forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact:
     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033